Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its ...

The in vivo gene editing pipeline is also advancing ... in their research and potential market impact. Additionally, Crispr Therapeutics AG plans to engage with regulators regarding B-cell ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

including notable advancements in Crispr Therapeutics AG’s pipeline and strategic partnerships. The company has shown promising progress with the Casgevy launch, evidenced by an increase in ...